Oryzon Genomics has strengthened its patent portfolio with the European grant of protection for iadademstat in combination with PD1/PD-L1 inhibitors in the treatment of cancer, including small-cell lung cancer.

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and European leader in epigenetics, today announced that the European Patent Office (EPO) has issued a Decision to Grant for its patent application EP20712594.9, entitled “Combinations of iadademstat for cancer therapy”. 

The allowed claims protect the use of iadademstat in combination with PD1 or PD-L1 inhibitors for the treatment of cancer, including small cell lung cancer (SCLC). Once formally granted, the patent will remain in force until at least 2040, excluding potential patent term extensions. Corresponding patents have already been allowed or granted in Australia and Russia, with additional applications pending in the United States, Japan, China, and other territories. 

“We are delighted to have secured this grant, which strengthens protection for iadademstat in combination with immune checkpoint inhibitors such as atezolizumab and durvalumab, a therapeutic approach we are actively pursuing in clinical trials”, said Neus Virgili, Oryzon’s Chief IP Officer. 

Iadademstat is currently being investigated in combination with PD-L1 inhibitors (atezolizumab or durvalumab) in first line, extensive-disease SCLC patients in a Phase I/II trial conducted and sponsored by the U.S. National Cancer Institute (NCI) under a Cooperative Research and Development Agreement (CRADA) with Oryzon. More than 30 sites accross the U.S. participate in the trial, including leading institutions such as Memorial Sloan Kettering Cancer Center, Johns Hopkins, City of Hope, Yale University
and the University of Chicago, among others.